Investors might want to bet on SESEN BIO, INC. (SESN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

SESEN BIO, INC. (SESN) closed the most recent trading day at $0.67, moving -1.59% from the previous trading session. This move lagged the S&P 500's daily loss of 1.13%. Meanwhile, the Dow lost 1.01%, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services ...

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicinium ®, also known as VB4-845 ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Sesen Bio, Inc. is a late-stage clinical company ...

Shares of Sesen Bio Inc. SESN were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete ...

Sesen Bio Inc (NASDAQ:SESN) shares are trading higher by 16.81% to $0.59 Friday morning after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive (the "Class ...

Drug developer Sesen Bio Inc. and its top executives were hit with a securities class action Thursday in New York Southern District Court in connection with the FDA's rejection of the company's ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive (the "Class ...